Published in final edited form as:

Ann Rheum Dis. 2016 January ; 75(1): 286–294. doi:10.1136/annrheumdis-2014-206074.

AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages

Yun Wang¹, Benoit Viollet^{2,3,4}, Robert Terkeltaub^{1,5}, and Ru Liu-Bryan^{1,5}

¹Department of Medicine, UCSD, San Diego, California, USA

²INSERM, U1016, Institut Cochin, Paris, France

³CNRS, UMR8104, Paris, France

⁴Université Paris Descartes, Sorbonne Paris Cité, Paris, France

⁵VA San Diego Medical Center, San Diego, California, USA

Abstract

Objective—AMP-activated protein kinase (AMPK) is metabolic biosensor with anti-inflammatory activities. Gout is commonly associated with excesses in soluble urate and in nutrition, both of which suppress tissue AMPK activity. Gout is driven by macrophage-mediated inflammation transduced partly by NLRP3 inflammasome activation and interleukin (IL)-1 β release. Hence, we tested the hypothesis that AMPK activation limits monosodium urate (MSU) crystal-induced inflammation.

Methods—We studied bone marrow-derived macrophages (BMDMs) from AMPK α 1 knockout and wild-type mice, and assessed the selective AMPK pharmacological activator A-769662 and a low concentration (10 nM) of colchicine. We examined phosphorylation (activation) of AMPK α Thr172, NLRP3 mRNA expression, and caspase-1 cleavage and IL-1 β maturation using western blot and quantitative RT-PCR approaches. We also assessed subcutaneous murine air pouch inflammatory responses to MSU crystals in vivo.

Results—MSU crystals suppressed phosphorylation of AMPK α in BMDMs. Knockout of AMPK α 1 enhanced, and, conversely, A-769662-inhibited MSU crystal-induced inflammatory responses including IL-1 β and CXCL1 release in vitro and in vivo. A-769662 promoted AMPK-dependent macrophage anti-inflammatory M2 polarisation and inhibited NLRP3 gene expression, activation of caspase-1 and IL-1 β . Colchicine, at low concentration (10 nM) achieved in gout flare prophylaxis dosing, promoted phosphorylation of AMPK α and macrophage M2 polarisation, and

BMJ Publishing Group Ltd (& EULAR) under licence.

Correspondence to Dr Ru Liu-Bryan, VA San Diego Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA; ruliub@ucsd.edu.

Contributors RT and RL-B contributed to study conception and design. YW and RL-B contributed to data acquisition and analysis. BV generated the AMPK α 1 KO mice. All authors contributed to data interpretation. YW, RT and RL-B contributed to drafting and revising the article.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data can be requested from the corresponding author.

reduced activation of caspase-1 and release of IL-1 β and CXCL1 by MSU crystals in BMDMs in vitro.

Conclusions—AMPK activity limits MSU crystal inflammation in vitro and in vivo, and transduces multiple anti-inflammatory effects of colchicine in macrophages. Targeting increased and sustained AMPK activation in inflammatory cells merits further investigation for enhancing efficacy of prophylaxis and treatment of gouty inflammation.

INTRODUCTION

Gout is a common inflammatory arthritis that can develop as a response to articular and soft tissue deposition of monosodium urate (MSU) crystals promoted by increased body urate burden and reflected by hyperuricaemia.¹² Increased body urate burden is driven by comorbidities such as obesity, metabolic syndrome and diabetes, hypertension and chronic kidney disease.¹² Nutritional excesses through consumption of alcohol, high purine meats and seafood, and fructose-sweetened sodas can promote increased body uric acid burden and trigger acute flares of arthritis in established gout.^{3–6} Clearly, not all subjects with increased body uric acid burden develop tissue urate crystal deposition, and there is marked variability in the frequency and severity of inflammatory arthritis in patients with established tissue urate crystal deposition and symptomatic gout.² Some variability in the ability of urate crystals to cause inflammation in the host may be due to the capacity of diet-modulated free fatty acids to prime TLR2-mediated signalling in macrophages.⁷⁸ Moreover, changes in cellular bioenergetics, regulated by nutritional factors and comorbidities, can reprogram inflammatory responses.⁹¹⁰

The serine/threonine protein kinase AMP-activated protein kinase (AMPK) is a cellular energy biosensor,¹¹¹² which is activated by stressors that increase AMP:ATP ratio (eg, nutrient deprivation, hypoxia, exercise).¹¹¹² Conversely, soluble urate itself,¹³¹⁴ and alcohol, fructose intake and other nutritional stressors inhibit tissue AMPK activity.^{15–17} Moreover, tissue AMPK activity is diminished in obesity, type 2 diabetes, metabolic syndrome and these linked metabolic disorders associated with both low-grade adipose tissue inflammation and increased prevalence of gout.¹⁸¹⁹

MSU crystal interaction with complement and resident cells induces acute inflammation in large part through expression of nuclear factor (NF)- κ B-dependent pro-inflammatory cytokines (eg, pro-interleukin (IL)-1 β , neutrophil chemotactic chemokines CXCL8 (IL-8), CXCL1) and macrophage lineage cell IL-1 β maturation and release via the activated NLRP3 inflammasome.^{20–22} Unfortunately, many patients with gout have contraindications or intolerance to, or failure of conventional anti-inflammatory agents (non-steroidal anti-inflammatory drugs, corticosteroids, colchicine) for the prevention and treatment of gouty arthritis.²³ Understanding and increasing options to prevent and treat gouty arthritis could advance care. In this context, activated AMPK is anti-inflammatory partly through inhibition of NF- κ B.²⁴ Moreover, activation of AMPK is induced by certain drugs already in the clinic for arthritis and other diseases (eg, methotrexate, high-dose aspirin, metformin),¹⁰²⁵ and by other agents, including the selective and direct activator A-769662.¹⁰²⁵

In this study, we performed translational studies on effects of pharmacological activation of AMPK on MSU crystal-induced inflammatory responses in bone marrow-derived macrophages (BMDMs) in vitro and in the synovium-like mouse subcutaneous air pouch model in vivo. Since inhibition of AMPK impairs microtubule stabilisation,²⁶ we also tested the specific hypothesis that the microtubule-stabilising agent colchicine could limit inflammatory responses of macrophages to MSU crystals by regulating AMPK activity. Our results suggest a novel mechanism by which AMPK activity regulation contributes to the development and intensity of tissue inflammation in gout and transduces many of the anti-inflammatory prophylaxis and therapeutic effects of colchicine for gouty inflammation.

METHODS

Reagents

All chemical reagents were from Sigma-Aldrich (St. Louis, Missouri, USA), unless otherwise stated. MSU crystals were prepared as described,²⁷ suspended at 25 mg/mL in sterile, endotoxin-free phosphate buffered saline (PBS) and verified to be free of detectable lipopolysaccharide contamination by Limulus lysate assay (Lonza, Walkersville, Maryland, USA). A-769662 was from LC laboratories (Woburn, Massachusetts, USA). Antibodies to phospho-p65 (Ser536) and total p65 NF- κ B subunit, phospho-AMPK α (Thr172) and total AMPK α (recognising both AMPK α isoforms) were from Cell Signaling Technology (Danvers, Massachusetts, USA). AMPK α 1 antibody was from Abcam (Cambridge, Massachusetts, USA). IL-1 β antibody was from BioVision (Milpitas, California, USA). Antibodies to caspase-1 (p20) and cleaved caspase-1 (p10) were from AdipoGen International (San Diego, California, USA) and Santa Cruz Biotechnology (Santa Cruz, California, USA), respectively.

Mice

We studied AMPK α 1 knockout (KO) mice generated in Dr Benoit Viollet's lab and congenic wild-type (WT) mice on C57BL/6/129 background. All animal procedures were humanely performed with institutionally peer reviewed, approved protocols at San Diego, Virginia, USA.

Cell culture

Bone marrows from 7-week-old to 8-week-old AMPK α 1 KO and congenic WT mice were obtained by flushing femurs. BMDMs were then generated by culturing the cells from bone marrows in complete Roswell Park Memorial Institute (RPMI) media containing 10% fetal bovine serum (FBS), penicillin (100 U/mL) and streptomycin (100 μ g/mL) in the presence of macrophage colony-stimulating factor (M-CSF) (5 ng/mL) (R&D Systems). After 5–7 days, the M-CSF-derived macrophages were replated onto 24-well (5×10^5 /well) or 6-well plates (2×10^6 /well) and primed with 5 ng/mL granulocyte macrophage colony-stimulating factor (GM-CSF) (R&D Systems)^{28–30} for 24 h in complete RPMI media before treatment with indicated reagents in fresh RPMI containing only 1% FBS. Human monocytic THP-1 cells were maintained in complete RPMI supplemented with 2-mercaptoethanol (0.05 mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (10 mM) and sodium pyruvate (1 mM). Cells (1×10^6 cells/mL) were stimulated with 20 ng/mL phorbol 12-myristate 13-acetate

(PMA) for 24 h, and then cultured in fresh complete media for another 24 h before treated with indicated reagents in fresh medium containing only 1% FBS. Cell viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, Wisconsin, USA).

Western blot

Cells were lysed in RIPA buffer with 2 mM sodium vanadate and protease inhibitor cocktails (Roche, Mannheim, Germany). Cell lysates (10–15 µg) were separated by gradient 4%–20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Bio-Rad, Hercules, California, USA) probed with antibodies, exposed to SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, Massachusetts, USA) and visualised by radiography.

Cytokine analyses

Mouse IL-1β and CXCL1 (KC) and human IL-1β were measured using DuoSet ELISA (R&D Systems, Minneapolis, Minnesota, USA).

Quantitative RT-PCR (qPCR)

Total RNA was extracted and purified from cells using RNeasy Mini Kits (Qiagen, Hilden, Germany), with first strand cDNA generated via Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). Quantitative RT-PCR analysis of mRNA expression of NLRP3, IL-1β, NOS2 and arginase-1 was performed using LightCycler 480 (Roche) for 35 cycles. Fold changes were calculated by 2^{-ct} methods, relative to the housekeeping GAPDH mRNA expression. Sequences of all primers are listed in online supplementary table.

Subcutaneous air pouch model

Subcutaneous pouches were generated by repeated injection of sterile air in 6-week-old to 8-week-old mice.²⁷ After 7 days, MSU crystals (3 mg) in 1 mL of sterile endotoxin-free PBS were injected into the air pouch.²⁷ Where indicated, A-769662 (10 µL of 100 mM stock in dimethyl sulfoxide (DMSO) diluted in 200 µL PBS) was injected into the pouch 1 h before crystal injection. Mice were euthanized 6 h after MSU crystal injection. Pouch fluids were harvested, and cells in pouch fluid were then characterised by staining with HEMA 3 (Fisher, Kalamazoo, Michigan, USA). Pouch fluid supernatants were subjected to ELISA analysis for cytokines, which were expressed as total amount of each cytokine per pouch by multiplying concentration of each cytokine with the total volume of pouch fluid. Air pouch tissues were fixed in 10% formalin, embedded in paraffin and sectioned for histological analysis of infiltrating inflammatory cells by H&E staining.

Statistical analyses

Data are presented as either mean values±SD or mean±SEM as indicated. Statistical analyses were performed by two-way analysis of variance with Bonferroni post hoc test using GraphPad Prism software, V.5, or by Student t test. p Values <0.05 were considered significant.

RESULTS

Pharmacological AMPK activation suppressed MSU crystal-induced inflammatory responses in macrophages in vitro.

MSU crystals decreased AMPK α activity in macrophages (figure 1A), consistent with prior evidence that some inflammatory stimuli, including IL-1 β , inhibit phosphorylation (at Thr172 of the catalytic domain) of the α subunit of heterotrimeric AMPK critical for AMPK activity.³¹ Pretreatment of BMDMs with the selective AMPK activator A-769662 (0.125 mM) increased basal phosphorylation of AMPK α and prevented de-phosphorylation of AMPK α in response to MSU crystals (figure 1A). In parallel, A-769662 (0.125 mM) inhibited MSU crystal-induced release of IL-1 β and CXCL1 (figure 1B, C). Similar effects were also observed with the indirect AMPK activator metformin (see online supplementary figure S1).

AMPK α 1 deficiency significantly enhanced inflammatory responses to MSU crystals both in vitro and in vivo

In macrophages, of the two AMPK α isoforms expressed, AMPK α 1 is the predominant activated one.³² Here, we observed that expression of total AMPK α was largely decreased and phosphorylation of AMPK α was diminished in AMPK α 1 KO compared with WT BMDMs (figure 2A). AMPK α 1 KO BMDMs demonstrated increased release of IL-1 β and CXCL1 by MSU crystals in vitro (figure 2B, C).

MSU crystal-induced leucocyte infiltration was significantly increased in AMPK α 1 KO air pouch cavities (figure 3A and top panel of 3B), as were oedema and associated leucocyte-rich inflammatory thickening in the lining of the AMPK α 1 KO air pouch tissues compared with congenic WT mice (bottom panel of figure 3B). These changes were associated with increased pouch fluid IL-1 β and CXCL1 in AMPK α 1 KO mice (figure 3C,D).

Pharmacological activation of AMPK by A-769662 inhibited MSU crystal-induced inflammation in vivo

Western blot analysis of protein lysates of the air pouch lining tissues confirmed increased AMPK α phosphorylation by A-769662 (figure 4A). A-769662 pretreatment in vivo decreased MSU crystal-induced leucocyte ingress into air pouch fluid (figure 4B, top panel of figure 4C), as well as swelling and associated inflammation of air pouch lining tissues (bottom panel of figure 4C). Moreover, induction of IL-1 β and CXCL1 by MSU crystals was significantly inhibited by A-769662 (figure 4D, E).

A-769662 inhibited multiple MSU crystal-induced inflammatory responses and stimulated anti-inflammatory M2 macrophage polarisation in vitro.

MSU crystal-induced phosphorylation of NF- κ B p65 subunit (Ser536) was inhibited by A-769662 (0.125 mM) in BMDMs (figure 5A). Moreover, qRT-PCR analysis demonstrated that A-769662 significantly inhibited MSU crystal-induced mRNA expression of IL-1 β and NLRP3 (figure 5B), transcriptional events known to be NF- κ B-mediated.³³ IL-1 β is

generated as an inactive precursor pro-IL-1 β , cleaved by activated caspase-1 to form mature and bioactive IL-1 β .^{20–22} A-769662 did not significantly affect pro-caspase-1 protein expression in the presence or absence of MSU crystals, but attenuated expression of cleaved caspase-1 (p10 or p20 active forms) in response to MSU crystals (figure 5C). A-769662 also inhibited MSU crystal-induced protein expression of both pro-IL-1 β and cleaved IL-1 β (figure 5C). In contrast, MSU crystal-induced expression of cleaved caspase-1 and cleaved IL-1 β were further enhanced in AMPK α 1 deficient BMDMs compared with congenic WT BMDMs (data not shown). Finally, qRT-PCR analysis of gene expression of arginase-1, a marker for anti-inflammatory M2 macrophages, and NOS2, a marker for inflammatory M1 macrophages,³⁴ demonstrated that priming mouse macrophages (M-CSF-derived) with GM-CSF shifted macrophages towards M1 phenotype, evidenced by the markedly decrease in the ratio of arginase-1/NOS2 in GM-CSF-primed macrophages compared with naive M-CSF-derived macrophages (see online supplementary figure S2). Moreover, A-769662 (0.125 mM) increased the ratio of arginase-1/NOS2 in WT but not AMPK α 1 KO GM-CSF-primed macrophages (figure 5D). In contrast, IL-4, a known cytokine to induce M2 phenotype, increased the ratio of arginase-1/NOS2 in both WT and AMPK α 1 KO GM-CSF-primed macrophages to similar levels (data not shown). These results suggested that A-769662 promoted AMPK-dependent macrophage polarisation to M2 phenotype.

Colchicine inhibited MSU crystal-induced inflammatory responses and promoted macrophage M2 polarisation mediated by induction of AMPK activation in vitro.

Colchicine increased AMPK α phosphorylation in cultured mouse BMDMs (figure 6A), and did so at 10 nM concentration comparable with peak plasma concentrations clinically achieved in low-dose colchicine gout prophylaxis and treatment.³⁵³⁶ No significant alteration in cell viability was observed under this condition (data not shown). To determine how colchicine activates AMPK, we examined the effect of colchicine on phosphorylation of LKB1, the major upstream activating kinase for AMPK,¹² and protein expression of phosphatase 2A and 2C, two negative regulators of AMPK α phosphorylation.¹² Colchicine (10 nM) increased phosphorylation of LKB1 (figure 6A), but did not affect PP2A and PP2C expression (online supplementary figure S3), which suggested involvement of LKB1 in AMPK activation. Colchicine (10 nM) also increased protein expression of total AMPK α (figure 6A), but did not significantly alter mRNA levels of AMPK α 1 or AMPK α 2, assessed by qRT-PCR (see online supplementary figure S4). Colchicine appeared to regulate AMPK α expression at the translational level as it did not increase AMPK α protein expression in the presence of protein synthesis inhibitor cycloheximide (see online supplementary figure S5).

Colchicine promoted the potential for AMPK-dependent M2 macrophage polarisation by increasing the ratio of arginase-1 to NOS2 mRNA expression significantly in WT but not AMPK α 1 KO BMDMs (figure 6B). Unlike A-769662, colchicine (10 nM) did not inhibit NF- κ B-dependent mRNA expression of IL-1 β and NLRP3 (data not shown) and protein expression of pro-caspase-1 and pro-IL-1 β (figure 6C). However, colchicine (10 nM) partially inhibited caspase-1 cleavage and pro-IL-1 β to IL-1 β maturation, and release of IL-1 β and CXCL1 in response to MSU crystals in mouse BMDMs (figure 6C, D). These

inhibitory effects were at least partly mediated through AMPK since colchicine failed to inhibit release of IL-1 β and CXCL1 in AMPK α 1 KO BMDMs (figure 6D).

DISCUSSION

Our study revealed that AMPK activity regulated development of tissue inflammatory responses to MSU crystals. Specifically, we observed that decreased mouse macrophage AMPK activity promoted a state of increased inflammatory responsiveness to MSU crystals, demonstrated by induction of NF- κ B activation, IL-1 β and NLRP3 mRNA expression at transcriptional level, as well as caspase-1 activation and IL-1 β maturation at post-translational level. Significantly, pharmacological activation of AMPK by A-769662 inhibited NLRP3 inflammasome activation at both transcriptional and post-translational levels in mouse macrophages in response to MSU crystals. We also demonstrated that A-769662 inhibited MSU-induced caspase-1 activation and IL-1 β maturation, and IL-1 β release in PMA-differentiated human monocytic THP-1 cells (see online supplementary figure S6).

We discovered AMPK activation to be a molecular target of colchicine in macrophages. Translational relevance was supported by our observation that colchicine upregulated activation of AMPK in macrophages at 10 nM, comparable with peak plasma concentration clinically achieved, and effective, in gout prophylaxis and treatment.³⁵³⁶ Colchicine (10 nM) inhibited MSU crystal-induced release of both IL-1 β and CXCL1 in an AMPK-dependent manner. Unlike A-769662, colchicine appeared to inhibit MSU crystal-induced IL-1 β generation only at the post-translational level as it did not affect pro-caspase-1 and pro-IL-1 β protein expression. Colchicine (10 nM) also increased the expression of the antioxidant thioredoxin-1 (see online supplementary figure S7), which was pertinent because dysregulation of redox balance between thioredoxin and thioredoxin-interacting protein promotes oxidative stress in processes activating the NLRP3 inflammasome.³⁷³⁸ Mechanistically, colchicine may promote macrophage AMPK activity by effects including increased phosphorylation (activation) of LKB1, the major upstream kinase of AMPK, and elevated of total AMPK α protein expression. How colchicine regulates LKB1 activation in macrophages remains to be determined. Nevertheless, colchicine effects on the AMPK activation process were at least partially selective since colchicine did not modulate the PP2A and PP2C α phosphatases that dephosphorylate AMPK α and thereby deactivate AMPK.

This study identified shared effects of AMPK activity and colchicine on macrophage anti-inflammatory M2 polarisation in vitro. In gout, such differentiation changes appear consequential since some M2 macrophage subsets promote resolution of inflammation induced by MSU crystals by mechanisms including ingestion of MSU crystals and apoptotic neutrophils,³⁹ with associated increases in transforming growth factor β and other mediators that dampen acute inflammation.⁴⁰ We observed that both A-769662 and colchicine were able to increase ratio of arginase-1 (M2 marker) to NOS2 (M1 marker), which required AMPK. This result reinforced the previous finding that AMPK activation promotes M1–M2 macrophage polarisation.⁴¹⁴²

Colchicine is now added to the list of indirect AMPK activation-promoting drugs already in the clinic for arthritis and other diseases including methotrexate, high-dose aspirin (acetylsalicylic acid) and metformin.¹⁰²⁵ Our studies showed that metformin was able to inhibit MSU crystal-induced release inflammatory cytokines in mouse macrophages in vitro. This is clinically pertinent since metformin is used in the clinic as an insulin-sensitiser for metabolic syndrome and type II diabetes. As such, the potential for integrating metformin into management of both gout and insulin resistance merits further investigation. Furthermore, we found that aspirin and sodium salicylate, at high doses (3 mM) achievable in human anti-inflammatory therapy⁴³⁴⁴), enhanced phosphorylation of AMPK α and significantly inhibited MSU crystal-induced IL-1 β release in mouse BMDMs in vitro (see online supplementary figure S8).

Limitations of this study included our focus on cultured macrophages and murine model gout. It remains to be determined whether activation of AMPK inhibits initiation of acute arthritis and promotes the resolution phase in gout-like inflammation. Also beyond the scope of this study was examination whether the basis for reported priming effects of high ambient levels of uric acid on phagocyte activation responses are mediated by the capacity of high concentration of soluble urate to decrease tissue AMPK activity.¹⁴ Finally, it is likely that not all models of nutritional excesses, obesity and gout-like inflammation in body cavities may give as consistent results for AMPK effects as those in the current study. For example, in a recent study of effects of 12 weeks of high-fat diet-induced obesity on the inflammatory phenotype of resident C57BL/6 mice peritoneal macrophages, there was increased pro-inflammatory background function of peritoneal macrophages.⁴⁵ However, intraperitoneal MSU crystal injection unexpectedly decreased the high background levels of IL-6, MCP-1, KC and GM-CSF levels in the obese mice and failed to increase phagocyte recruitment into the peritoneal cavity.⁴⁵

In conclusion, activated AMPK suppresses inflammatory responses induced by MSU crystals both in vitro and in vivo, and transduces multiple anti-inflammatory effects of colchicine in macrophages. Since soluble urate itself,¹³¹⁴ and alcohol consumption, and multiple nutritional stressors and obesity and metabolic syndrome decrease tissue AMPK activity,^{15–17} our results implicate that decreased AMPK activity may promote in vivo inflammatory responses to MSU crystal deposits in humans with specific comorbidities and nutritional stressors. It will be of interest to determine whether variability in tissue AMPK activity in humans contributes to the observations that gout only develops in a minority, and over variable periods of time, in subjects with increased body uric acid burden, and that there is marked variability in the frequency and severity of inflammatory arthritis in patients with established MSU crystal deposition and symptomatic gout.² Many patients with gout have limited safe and effective anti-inflammatory treatment options.²³ Targeting increased and sustained activation of AMPK in inflammatory cells, and potentially in resident joint tissues, via diet and lifestyle measures and pharmacological agents, merits further investigation for potential capacity to enhance efficacy of prophylaxis and treatment of gouty inflammation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding This work was financially supported by the VA Research Service and grants from the Arthritis Foundation and NIH (PAG07996, T32 AR06419).

REFERENCES

1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. *Am J Med.* 2012; 125:679–87. e1. [PubMed: 22626509]
2. Liu-Bryan, R.; Terkeltaub, R. Tophus biology and pathogenesis of monosodium urate crystal-induced inflammation. In: Gout TR, other crystal arthropathies. , editor. Elsevier health sciences Elsevier. 2011. p. 59-71.
3. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. *Ann Rheum Dis.* 2012; 71:1448–53. [PubMed: 22648933]
4. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. *Lancet.* 2004; 363:1277–81. [PubMed: 15094272]
5. Neogi T, Chen C, Niu J, et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. *Am J Med.* 2014; 127:311–18. [PubMed: 24440541]
6. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. *BMJ.* 2008; 336:309–12. [PubMed: 18244959]
7. Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. *Arthritis Rheum.* 2010; 62:3237–48. [PubMed: 20662061]
8. Mylona EE, Mouktaroudi M, Crisan TO, et al. Enhanced interleukin-1 β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. *Arthritis Res Ther.* 2012; 14:R158. [PubMed: 22762240]
9. Liu TF, Brown CM, El Gazzar M, et al. Fueling the flame: bioenergy couples metabolism and inflammation. *J Leukoc Biol.* 2012; 92:499–507. [PubMed: 22571857]
10. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. *Nature.* 2013; 493:346–55. [PubMed: 23325217]
11. Steinberg GR, Kemp BE. AMPK in Health and Disease. *Physiol Rev.* 2009; 89:1025–78. [PubMed: 19584320]
12. Witczak CA, Sharoff CG, Goodyear LJ. AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. *Cell Mol Life Sci.* 2008; 65:3737–55. [PubMed: 18810325]
13. Lanaspas MA, Cicerchi C, Garcia G, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. *PLoS ONE.* 2012; 7:e48801. [PubMed: 23152807]
14. Cicerchi C, Li N, Kratzer J, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. *FASEB J.* 2014; 28:3339–50. [PubMed: 24755741]
15. Shearn CT, Backos DS, Orlicky DJ, et al. Identification of 5' AMP-activated Kinase as a Target of Reactive Aldehydes during Chronic Ingestion of High Concentrations of Ethanol. *J Biol Chem.* 2014; 289:15449–62. [PubMed: 24722988]
16. Axelsen LN, Lademann JB, Petersen JS, et al. Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation. *Am J Physiol Regul Integr Comp Physiol.* 2010; 298:R1560–70. [PubMed: 20357025]
17. Saha AK, Xu XJ, Balon TW, et al. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? *Cell Cycle.* 2011; 10:3447–51. [PubMed: 22067655]

18. Ruderman NB, Carling D, Prentki M, et al. AMPK, insulin resistance, and the metabolic syndrome. *J Clin Invest.* 2013; 123:2764–72. [PubMed: 23863634]
19. Viollet B, Mounier R, Leclerc J, et al. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. *Diabetes Metab.* 2007; 33:395–402. [PubMed: 17997341]
20. Busso N, So A. Mechanisms of inflammation in gout. *Arthritis Res Ther.* 2010; 12:206. [PubMed: 20441605]
21. Joosten LA, Ea HK, Netea MG, et al. Interleukin-1 β activation during Acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. *Joint Bone Spine.* 2011; 78:107–10. [PubMed: 21183380]
22. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. *J Clin Rheumatol.* 2013; 19:19–29. [PubMed: 23319019]
23. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. *Am J Med.* 2011; 124:155–63. [PubMed: 21295195]
24. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on health span and lifespan. *J Mol Med.* 2011; 89:667–76. [PubMed: 21431325]
25. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol.* 2012; 13:251–62. [PubMed: 22436748]
26. Nakano A, Kato H, Watanabe T, et al. AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. *Nat Cell Biol.* 2010; 12:583–90. [PubMed: 20495555]
27. Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. *Arthritis Rheum.* 2005; 52:2936–46. [PubMed: 16142712]
28. Fleetwood AJ, Lawrence T, Hamilton JA, et al. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. *J Immunol.* 2007; 178:5245–52. [PubMed: 17404308]
29. Sordi CA, Rose S, Court N, et al. GM-CSF priming drives bone marrow-derived macrophages to a pro-inflammatory pattern and downmodulates PGE2 in response to TLR2 ligands. *PLoS One.* 2012; 7:e40523. [PubMed: 22808181]
30. Shaw OM, Steiger S, Liu X, et al. GM-CSF drives MSU crystal-induced inflammatory macrophage differentiation and NLRP3 inflammasome upregulation in vivo. *Arthritis Rheumatol.* 2014; 66:2423–8. [PubMed: 24910235]
31. Terkeltaub R, Yang B, Lotz M, et al. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1 β and tumor necrosis factor α . *Arthritis Rheum.* 2011; 63:1928–37. [PubMed: 21400477]
32. Yang Z, Kahn BB, Shi H, et al. Macrophage α 1 AMP-activated protein kinase (α 1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. *J Biol Chem.* 2010; 285:19051–9. [PubMed: 20421294]
33. Qiao Y, Wang P, Qi J, et al. TLR-induced NF- κ B activation regulates NLRP3 expression in murine macrophages. *FEBS Lett.* 2012; 586:10226.
34. Classen A, Lloberas J, Celada A. Macrophage activation: classical versus alternative. *Methods Mol Biol.* 2009; 531:29–43. [PubMed: 19347309]
35. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum.* 2010; 62:1060–8. [PubMed: 20131255]
36. Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. *Rheumatology (Oxford).* 2014; 53:1920–26. [PubMed: 24758886]
37. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? *Nat Immunol.* 2012; 13:352–7. [PubMed: 22430788]

38. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. *Curr Opin Immunol.* 2013; 25:40–5. [PubMed: 23305783]
39. Rose DM, Sydlaske AD, Agha-Babakhani A, et al. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. *Arthritis Rheum.* 2006; 54:3363–71. [PubMed: 17009310]
40. Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. *Arthritis Rheum.* 2004; 50:2273–80. [PubMed: 15248227]
41. Sag D, Carling D, Stout RD, et al. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. *J Immunol.* 2008; 181:8633–41. [PubMed: 19050283]
42. Weng SY, Schuppan D. AMPK regulates macrophage polarization in adipose tissue inflammation and NASH. *J Hepatol.* 2013; 58:619–21. [PubMed: 23046670]
43. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. *Science.* 2012; 336:918–22. [PubMed: 22517326]
44. Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs? *Trends Endocrinol Metab.* 2013; 24:481–7. [PubMed: 23871515]
45. Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. *Arthritis Rheum.* 2007; 56:688–92. [PubMed: 17265505]

Figure 1.

Inhibition of de-phosphorylation of AMP-activated protein kinase (AMPK α) and inflammatory cytokine production by A-769662 in mouse bone marrow-derived macrophages (BMDMs) stimulated with monosodium urate (MSU) crystals in vitro. Mouse BMDMs primed with GM-CSF, as described in the Methods section, were pretreated with A-769662 (0.125 mM) for 1 h before stimulation with MSU crystals (0.2 mg/mL) for 16 h. Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/western blot analysis for phosphorylated and total AMPK α . β -Actin was used as a loading control (A). Densitometry analysis of phosphorylated AMPK relative to total AMPK presented as mean of three individual experiments. p Values are indicated in (A). The conditioned media was subjected to ELISA analysis for cytokines interleukin-1 β and CXCL1 (knockout (KC)) (B and C). Data shown as mean $\pm$ SD of at least three individual experiments. p Values shown in (B) and (C) as comparisons of MSU crystal-stimulated macrophages with and without A-769662 pretreatment.

Figure 2.

Enhanced monosodium urate (MSU) crystal-induced release of interleukin (IL)-1 β and CXCL1 in AMP-activated protein kinase (AMPK α 1)-deficient bone marrow-derived macrophages (BMDMs) in vitro. We stimulated GM-CSF-primed AMPK α 1 knockout (KO) and wild-type (WT) mouse BMDMs with MSU crystals (0.2 mg/mL) for 16 h. Cell lysates were analysed for phosphorylation of AMPK α 1, protein expression of AMPK α 1, total AMPK α (including both AMPK α 1 and AMPK α 2) and β -actin (loading control) by western blot (A). Release of IL-1 β and CXCL1 was analysed as described in figure 1 (B and C). Data shown as mean $\pm$ SD of at least three individual experiments. p Values shown in (B) and (C) as comparisons of AMPK α 1 KO and WT macrophages treated with MSU crystals.

Figure 3.

Enhanced inflammatory responses to monosodium urate (MSU) crystals in AMPK α 1 knockout mice in vivo. MSU crystals α (3 mg in 1 mL sterile phosphate buffered saline (PBS)) were injected into subcutaneous air pouches of AMP-activated protein kinase (AMPK α 1) knockout (KO) and wild-type (WT) mice. After 6 h, exudate leucocytes were counted (A) and synovial-like lining inflammatory responses assessed. Smears of cells from pouch exudates were stained with HEMA 3 (B, top panels). Paraffin sections of air pouch tissues were stained with H&E (B, bottom panels). Release of interleukin (IL)-1 β and CXCL1 was measured by ELISA from supernatants of air pouch exudates and expressed as total amount of each cytokine per pouch (ng/pouch) (C and D). Data shown in (A) as mean $\pm$ SEM of 15 mice in each group. Data shown in (B) as representative of three different experiments from 15 mice in each group. p Values shown in (A), (C) and (D) as comparisons of MSU crystal-treated WT and AMPK α 1 KO mice.

Figure 4.

Inhibition of monosodium urate (MSU) crystal-induced inflammatory responses by A-769662 in vivo. Air pouches were created in wild-type (WT) mice. One group of mice received A-769662 (10 μ L of 100 mM stock in dimethyl sulfoxide (DMSO) diluted in 200 μ L phosphate buffered saline (PBS)) injected directly into pouches 1 h before injection of MSU crystals (3 mg in 1 mL PBS). Another group of mice received DMSO diluted to 200 μ L PBS alone, used as controls. Six hours after injection of MSU crystals, exudates were collected and inflammatory responses analysed (B–E) as described in figure 3. Protein lysates of air pouch lining tissues were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/western blot analysis for phosphorylated and total AMP-activated protein kinase (AMPK α). β -Actin was used as a loading control (A). Data shown in (A) as representative of three different experiments. Data shown in (C) as representative of three different experiments from 18 mice in each group. Data shown in (B), (D) and (E) as mean $\pm$ SEM of 18 mice in each group. p Values shown in (B), (D) and (E) as comparisons of MSU crystal-treated mice with and without A-769662.

Figure 5.

Inhibition of nuclear factor (NF)- κ B-dependent interleukin (IL)-1 β and NLRP3 mRNA expression, caspase-1 activation and IL-1 β maturation in mouse bone marrow-derived macrophages (BMDMs) stimulated with monosodium urate (MSU) crystals, and promotion of anti-inflammatory M2 macrophage polarisation by A-769662 in vitro. Granulocyte macrophage colony-stimulating factor (GM-CSF)-primed mouse BMDMs (wild-type (WT)) were pretreated with A-769662 (0.125 mM) for 1 h before stimulation with MSU crystals (0.2 mg/mL) for 6 and 16 h. Phosphorylation of p65 NF- κ B subunit, IL-1 β and NLRP3 mRNA expression were determined from the 6 h-treatment group by western blot and quantitative RT-PCR analysis, respectively (A and B). Protein expression of pro-caspase-1, cleaved caspase-1, pro-IL-1 β and cleaved IL-1 β were examined after 16 h of treatment, via western blot (C). Expression of arginase-1 (M2-like) and NOS2 (M1-like) mRNA was determined by qRT-PCR, comparing GM-CSF-primed WT and AMPK α 1 knockout (KO) BMDMs with or without A-769662 for 6 h, and the ratios of arginase-1 and NOS2 mRNA were presented (D). Data in (A) and (C) as representative of three different experiments. Data in (B) and (D) as the mean $\pm$ SD from at least three individual experiments. p Values shown in (B) as comparisons of MSU crystal-stimulated macrophages with and without A-769662. p Value shown in (D) as comparison of WT macrophages with and without A-769662.

Figure 6.

Promotion of AMP-activated protein kinase (AMPK) phosphorylation and M2 polarisation and suppression of caspase-1 activation, interleukin (IL)-1 β maturation and release of IL-1 β and CXCL1 by low-dose colchicine in mouse bone marrow-derived macrophages (BMDMs) stimulated with monosodium urate (MSU) crystals in vitro. Granulocyte macrophage colony-stimulating factor (GM-CSF)-primed mouse BMDMs were stimulated with colchicine (10 nM) with and without MSU crystals (0.2 mg/mL) for 16 h. Cell lysates were analysed for both phosphorylated and total AMPK α and LKB1 (A), expression of pro-caspase-1, cleaved caspase-1, pro-IL-1 β and cleaved IL-1 β (C), and β -actin (loading control) by western blot. Densitometry analysis of phosphorylated AMPK and LKB1 relative to total AMPK and LKB1, respectively, was presented as mean of three individual experiments (A). Arginase-1 (M2) and NOS2 (M1) mRNAs were examined from GM-CSF-primed wild-type (WT) and AMPK α 1 knockout (KO) BMDMs in the presence or absence of 10 nM colchicine for 16 h, and using qRT-PCR, as above (B). Release of IL-1 β and CXCL1 was determined by ELISA of conditioned media from GM-CSF-primed WT and AMPK α 1 KO BMDMs treated with and without colchicine (10 nM) and MSU crystals (0.2 mg/mL) for 16 h (D). Data in (C) representative of three different experiments. Data in (B) and (D) shown as the mean $\pm$ SD from at least three individual experiments. p Values shown in (A) and (B) as comparisons of macrophages in the presence or absence of colchicine. p Values shown in (D) as comparisons of MSU crystal-stimulated WT macrophages in the presence or absence of colchicine.